Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06639594 · ClinicalTrials.gov registry record · Phase 1
Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study
A Phase 1 study of Impulse Control Disorder, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06639594 is a Phase 1 study of Impulse Control Disorder that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 103-participant average among 3 other Impulse Control Disorder trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06639594, a Phase 1 study of Impulse Control Disorder, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if accelerated rTMS (repetitive transcranial magnetic stimulation) can be used as a possible therapy for excessive eating.
Conditions Studied
Interventions
- DEVICE Repetitive Transcranial Magnetic Stimulation (rTMS)
Study Locations (1)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2027-11-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06639594
The ClinicalTrials.gov registry entry for NCT06639594 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 3 other Impulse Control Disorder trials with a reported enrollment target (71% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Impulse Control Disorder appearing as the primary indexed condition, and to 1 intervention - of which Repetitive Transcranial Magnetic Stimulation (rTMS) is the first listed.
NCT06639594 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06639594 about?
NCT06639594 is a clinical study titled "Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study". To learn if accelerated rTMS (repetitive transcranial magnetic stimulation) can be used as a possible therapy for excessive eating.
What is the current status of trial NCT06639594?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-11-21. Estimated completion is 2027-11-03.
What conditions does trial NCT06639594 study?
This clinical trial studies the following conditions: Impulse Control Disorder.
What interventions are being tested in trial NCT06639594?
The interventions under investigation include: Repetitive Transcranial Magnetic Stimulation (rTMS) (DEVICE).
Who is sponsoring clinical trial NCT06639594?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06639594 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Impulse Control Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.